Christophe F. Grosset

Strategic Lead - Marketscreener Italy

Because finance isn’t just about numbers, Christophe F. Grosset explores the ideas, trends and people reshaping it. Between Milan and Geneva, he highlights innovation, markets, and those reinventing the industry. Follow him on MarketScreener Italia — where finance meets curiosity.

UCB raises guidance on strength of its two flagship treatments, analysts applaud

Supported by sustained commercial momentum, the Belgian biopharmaceutical group (+13.05%, at EUR240.20) announced another increase in its financial targets for FY 2026. Strong revenue growth is generating significant operating leverage, allowing for a marked expansion in margins.

22 October 2026 at 08:05 pm AEDT

UCB

Discover our authors

Romain Fournier

Chief Editor

Tommy Douziech

Senior Analyst

Maya Patel

Analyst

Antoine Alves d'Oliveira

Journalist

Tony Grandsire

Junior Analyst

See all our authors

Latest analyses

	European corporate earnings set to get a boost from energy windfall
	Spotify exceeds forecasts, Carpenter Technology's shares plummet
	Greece, Egypt in talks to extend maritime zone further east
	Wall St opens lower as AI jitters return, oil rises
	TSX opens lower as mining, tech stocks weigh
	MIB retreats with banks and tech; Moncler stands out
	Namibia cuts 2026 growth forecast to 2.3% after weak first half
	China's Chip Catch-Up May Take Five Years: Miller
	India extends duty-free raw sugar import deadline to December 31
	Meta's credit risk indicator jumps to record high after results

All Analysis